Abstract: Importance: Fremanezumab, a fully humanized monoclonal antibody that targets calcitonin gene-related peptide, may be effective for treating episodic migraine. Conclusions and Relevance: Among patients with episodic migraine in whom multiple medication classes had not previously failed, subcutaneous fremanezumab, compared with placebo, resulted in a statistically significant 1.3- to 1.5-day reduction in the mean number of monthly migraine days over a 12-week period.
Source: Institute for Clinical and Economic Review (ICER)
A recently released Institute for Clinical and Economic Review (ICER) evidence report assessing the comparative clinical effectiveness and value of three calcitonin gene-related peptide (CGRP) inhibitors for prevention of migraine attacks found that the price of the therapies aligns with the value to patients for whom other preventive treatments have failed.
Read the report…
Source: American Academy of Neurology (AAN)
While it has been known that estrogen plays a role in migraine for women, new research shows that the female sex hormone may also play a role in migraine for men, according to a small study published in the June 27, 2018, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Source: American Headache Society
At the American Headache Society (AHS)’s 60th Annual Scientific Meeting, leading migraine experts are presenting five clinical studies that deepen the understanding of the effects of episodic and chronic migraine on women’s lives throughout the years, including their personal relationships and family life. Of the 37 million Americans who suffer from migraine, 28 million are women. Research indicates women experience migraine differently than men, and their episodes of migraine often last longer.
Source: Institute for Clinical and Economic Review
The Institute for Clinical and Economic Review released a final evidence report on three calcitonin gene-related peptide (CGRP) inhibitors for prevention of migraine. Panel members voted that evidence was adequate to demonstrate a net health benefit of the CGRP inhibitors for individuals with chronic migraine and no other available treatment options.
Read Final Evidence Report and Report-at-a-Glance
Source: Newcastle University, U.K.
Experts at Newcastle University say introducing an electronic referral system to speed up diagnosis and treatment is likely to improve quality of life and save money.
Source: Frontiers in Molecular Biosciences
The study, in Frontiers in Molecular Biosciences, suggests that sex hormones affect cells around the trigeminal nerve and connected blood vessels in the head, with estrogens — at their highest levels in women of reproductive age — being particularly important for sensitizing these cells to migraine triggers.
American Academy of Pain Medicine